OSSIANY MONS-FIALLO: Open Payments
NPI 1811675457 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$403 in 18 payments from 9 companies in 2025. Trend: 2023 $109 · 2024 $314 · 2025 $403
Food & beverage: $403
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $74 |
| Merck Sharp & Dohme LLC | 3 | $68 |
| Lilly USA, LLC | 3 | $66 |
| TerSera Therapeutics LLC | 2 | $57 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Stemline Therapeutics Inc. | 2 | $36 |
| Novocure Inc. | 1 | $22 |
| Janssen Biotech, Inc. | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: Enhertu, VERZENIO, Zoladex, KEYTRUDA, Orserdu, LYNPARZA, DATROWAY, Optune Lua (NovoTTF-200T).
Industry payments across FL — which companies pay providers there.
